Caremark Rx Inc

Caremark Rx — Merger or Acquisition (January 2007)

24 slides from Caremark Rx's merger presentation, Jan 10, 2007

  1. Slide 1: Filed by Caremark Rx, Inc. Pursuant to Rule 425

    1 Filed by Caremark Rx, Inc. Pursuant to Rule 425 under the Securities Act of 1933 and Deemed Filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934 Subject Company: Caremark Rx, Inc. Commission File No.: 001-14200

  2. Slide 2: Creating the Premier Pharmaceutical Services and Integrated Healthcare Provider

    2 Mac Crawford Chairman, President and CEO JP Morgan 25 Annual Healthcare Conference January 10, 2007 th Creating the Premier Pharmaceutical Services and Integrated Healthcare Provider

  3. Slide 3: Forward-looking statements

    3 This document contains certain forward-looking statements about Caremark and CVS. When used in this document, the words “anticipates”, “may”, “can”, “believes”, “expects”, “projects”, “intends”, “likely”, “will”, “to be” and any similar expressions and any other statements that are not historical

  4. Slide 4: Additional information about the proxy statement/prospectus

    4 Caremark and CVS filed a joint proxy statement/prospectus with the SEC in connection with the proposed merger. Caremark and CVS urge investors and stockholders to read the joint proxy statement/prospectus and any other relevant documents filed by either party with the SEC because they contain impo

  5. Slide 5: Express Scripts Proposal Not in Best Interests

    5 No strategic benefits Financial benefits are illusory Risk of antitrust delay likely Significant business risk Diminished financial flexibility Integration track record questionable Express Scripts Proposal Not in Best Interests of Shareholders, Customers and Consumers

  6. Slide 6: Express Scripts Proposal: Strategic Rationale

    6 Does not create competitive advantages Defensive reaction out of concern about enhanced competition Constructed to disrupt CVS/Caremark merger Express Scripts Proposal Not in Best Interests of Shareholders, Customers and Consumers Strategic Rationale

  7. Slide 7: Express Scripts Proposal: Financial Risk

    7 Lost business & negative synergies could offset purported synergies Synergy calculation questionable Express Scripts Proposal Not in Best Interests of Shareholders, Customers and Consumers Financial Risk Does not create competitive advantages Defensive reaction out of concern about enhanced compet

  8. Slide 8: Express Scripts Proposal: Antitrust Risk

    8 Delay will destroy 2007 and perhaps 2008 selling season Enforcement agencies could impose adverse conditions Express Scripts Proposal Not in Best Interests of Shareholders, Customers and Consumers Antitrust Risk Lost business & negative synergies could offset purported synergies Synergy calculatio

  9. Slide 9: Express Scripts Proposal: Business Risk

    9 Clients overwhelmingly negative Risk of substantial client attrition Express Scripts Proposal Not in Best Interests of Shareholders, Customers and Consumers Business Risk Delay will destroy 2007 and perhaps 2008 selling season Enforcement agencies could impose adverse conditions Antitrust Risk Los

  10. Slide 10: Express Scripts Proposal: Financial Position

    10 Limited capital for investment in existing business, strategic opportunities, dividends and share repurchases ESRX recently placed on negative watch by rating agencies Express Scripts Proposal Not in Best Interests of Shareholders, Customers and Consumers Financial Position Clients overwhelmingly

  11. Slide 11: Express Scripts Proposal: Management Team

    11 No experience with large-scale merger integration Recent integration track-record questionable Express Scripts Proposal Not in Best Interests of Shareholders, Customers and Consumers Management Team Limited capital for investment in existing business, strategic opportunities, dividends and share

  12. Slide 12: Express Scripts Proposal Not in Best Interests (summary)

    12 No experience with large-scale merger integration Recent integration track-record questionable Limited capital for investment in existing business, strategic opportunities, dividends and share repurchases ESRX recently placed on negative watch by rating agencies Clients overwhelmingly negative Ri

  13. Slide 13: Value: CVS merger versus Express Scripts

    13 • Significant strategic benefit • Solid financial benefits • Clients supportive • Q1 Close • Strong management team • No strategic advantage • Financial benefits suspect • Client attrition • Q3 close or later • Questionable recent performance & integrations Value

  14. Slide 14: CVS/Caremark Merger Capitalizes on Evolving Industry Trends

    14 CVS Merger Benefit Market Trends CVS/Caremark Merger Capitalizes on Evolving Industry Trends In store enrollment and consultation; Medication Therapy Management Medicare Part D More transparency at point of sale - consumer able to make totally informed decisions Cost Shift to Consumer Retail loca

  15. Slide 15: CVS/Caremark Merger is in Best Interest

    15 Significant strategic benefits Financial benefits are concrete and conservative No antitrust risk Business disruption minimal Enhanced financial position Proven management teams CVS/Caremark Merger Enhances Shareholder Value CVS/Caremark Merger is in Best Interest of Shareholders, Customers and C

  16. Slide 16: Strategic Benefits

    16 Logical evolution to better serve customers Caremark will be an even more effective PBM Will create differentiated services CVS/Caremark Merger Enhances Shareholder Value Strategic Benefits

  17. Slide 17: Financial Benefits

    17 At least $500 million in validated cost synergies with additional cost and revenue synergy opportunities CVS/Caremark Merger Enhances Shareholder Value Financial Benefits Logical evolution to better serve customers Caremark will be an even more effective PBM Will create differentiated services St

  18. Slide 18: Antitrust Status

    18 HSR period expired 12/20/06 – no risk CVS/Caremark Merger Enhances Shareholder Value Antitrust Status At least $500 million in validated cost synergies with additional cost and revenue synergy opportunities Financial Benefits Logical evolution to better serve customers Caremark will be an even mo

  19. Slide 19: Business Opportunity

    19 Clients overwhelmingly positive Could enhance selling season results Minimal integration risk CVS/Caremark Merger Enhances Shareholder Value Business Opportunity HSR period expired 12/20/06 – no risk Antitrust Status At least $500 million in validated cost synergies with additional cost and reven

  20. Slide 20: Financial Flexibility

    20 Flexibility for investments in existing business, strategic opportunities, dividends and share repurchases CVS/Caremark Merger Enhances Shareholder Value Financial Flexibility Clients overwhelmingly positive Could enhance selling season results Minimal integration risk Business Opportunity HSR pe

  21. Slide 21: Management Teams

    21 Proven track-records with large scale acquisition integration History of exceeding stated synergies Visionary leadership CVS/Caremark Merger Enhances Shareholder Value Flexibility for investments in existing business, strategic opportunities, dividends and share repurchases Financial Flexibility

  22. Slide 22: CVS/Caremark Merger Benefits Summary

    22 Flexibility for investments in existing business, strategic opportunities, dividends and share repurchases Proven track-records with large scale acquisition integration History of exceeding stated synergies Visionary leadership Clients overwhelmingly positive Minimal integration risk Expect Q1 cl

  23. Slide 23: Board conclusion on Express Scripts proposal

    23 Our Board gave careful consideration to the Express Scripts proposal. In the end, our conclusion was simple and straightforward: Express’ proposal is not in the best interests of Caremark, its shareholders, customers and consumers. Caremark believes that future success does not lie in simply crea

  24. Slide 24: Creating the Premier Pharmaceutical Services and Integrated Healthcare Provider

    24 Mac Crawford Chairman, President and CEO JP Morgan 25 Annual Healthcare Conference January 10, 2007 th Creating the Premier Pharmaceutical Services and Integrated Healthcare Provider

Caremark RX — Merger or Acquisition (January 2007) on 6ix